In the past 40 years, there has been a large increase in the number of people living with high blood pressure worldwide because of population growth and ageing—rising from 594 million in 1975 to over 1.1 billion in 2015.
A growing understanding of the highly "plastic," changeable nature of the brain--from the level of DNA, proteins, neuronal connections and networks, up to communication across brain regions--is driving the development of new therapeutic approaches to treat chronic pain, stroke, Parkinson´s disease, and a variety of other disorders described in an article in Alternative and Complementary Therapies, a journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Alternative and Complementary Therapies website until December 16, 2016.
Atrial fibrillation patients who use the drug, warfarin, to prevent harmful blood clots from forming in their hearts to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.
We are at the point of paradigm shift in treating stroke victims. High tech solutions are about to bring improvements that have been unthinkable. Bionik Laboratories is a pioneer in the field with a clear path to extraordinary growth.
Researchers from the San Francisco Veterans Affairs Medical Center and UCSF, and CalciMedica, Inc., are presenting a poster at the 46th annual Society for Neuroscience meeting in San Diego describing the use of calcium release-activated calcium (CRAC) channel inhibitors in traumatic brain injury (TBI). The poster, to be presented on Wednesday, November 16th, is titled "Calcium release-activated calcium (CRAC) channel inhibition protects against experiment brain injury by inhibiting microglial activation".
CLEVELAND, Oct. 17, 2016 -- (Healthcare Sales & Marketing Network) -- Synapse Biomedical Inc. (www.synapsebiomedical.com) announced that the results of a small French trial (RespiStimALS), designed to assess the NeuRx® Diaphragm Pacing System (DPS) in newly diagnosed ALS patients, were published in Lancet Neurology.
GALWAY, Ireland--(Healthcare Sales & Marketing Network)--Neuravi, a company dedicated to improving clinical outcomes for stroke patients, today announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available enhancements to the EmboTrap stent retriever platform, the EmboTrap® II Revascularization Device.
Neuravi has announced that Robert Colloton has joined the company’s senior management team as vice president of US Sales and Marketing.
The Penumbra 3D trial of the company’s 3D revascularisation device has successfully met the primary trial endpoints, demonstrating non-inferiority in both safety and efficacy of the company’s next-generation stent retriever when used with Penumbra System aspiration devices compared to Penumbra System aspiration devices alone.
Relievant Medsystems has received US Food and Drug Administration (FDA) 510(k) clearance for the Intracept intraosseous nerve ablation system.
Among patients with one to three brain metastases, the use of stereotactic radiosurgery alone, compared with stereotactic radiosurgery combined with whole brain radiotherapy, resulted in less cognitive deterioration at three months, according to a study published in JAMA.
A study recently published in the journal Neuromodulation suggests that earlier consideration of spinal cord stimulation in chronic pain care continuum could have a positive impact on patient outcomes, with reductions in hospitalisations, clinic visits, and opioid usage.
In a report published online in the Lancet, investigators describe the results of the phase 1, first-in-man study of human neural stem cells in patients with chronic ischaemic stroke (PISCES study). In their study, Dheeraj Kalladka and others found that stem cell treatment was associated with improved neurological function and induced no cell-related adverse events.
The US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) to Monteris Medical to evaluate the NeuroBlate system in patients newly diagnosed with glioblastoma multiforme. With this approval, Monteris will initiate the Feasibility Study on Laser Interstitial Thermal Ablation for the Treatment of Newly Diagnosed GBM (FLAG), an open-label, prospective study that will be conducted in five sites in the USA.
Rapid Medical has announced that its Comaneci adjustable remodelling mesh has exceeded 500 successfully treated aneurysms worldwide. This milestone comes two years after the company launched the device in Europe.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos